Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
secukinumab Q4W · 1 trial · 1 indication
Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model.
| Arm | Type | Description |
|---|---|---|
| Cutaneous lichen planus secukinumab 300mg Q4W | EXPERIMENTAL | Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in cutaneous lichen planus patients |
| Cutaneous lichen planus placebo | PLACEBO_COMPARATOR | Placebo in 1ml PFS in cutaneous lichen patients |
| Mucosal lichen planus secukinumab 300 mg Q4W | EXPERIMENTAL | Secukinumab 300 mg every 4 weeks provided in pre-filled syringe in mucosal lichen planus patients. |
| Mucosal lichen planus placebo | PLACEBO_COMPARATOR | Placebo 1 ml PFS in mucosal lichen planus patients |
| Lichen planopilaris secukinumab 300 mg Q4W | EXPERIMENTAL | Secukinumab 300 mg every 4weeks provided in pre-filled syringe in lichen planopilaris patients. |
| Lichen planopilaris placebo | PLACEBO_COMPARATOR | Placebo in 1ml PFS in lichen planopilaris patients |
| Cutaneous lichen planus placebo to secukinumab 300 mg Q2W | EXPERIMENTAL | Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2 |
| Mucosal lichen planus placebo to secukinumab 300 mg Q2W | EXPERIMENTAL | Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2 |
| Lichen planopilaris placebo to secukinumab 300 mg Q2W | EXPERIMENTAL | Non responder patients on placebo in TP 1 received secukinumab 300 mg Q2W in TP 2 |
| Name | Type | Description |
|---|---|---|
| secukinumab 300 mg Q4W | DRUG | secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe. |
| secukinumab 300 mg Q2W | DRUG | secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe. |
| Placebo | OTHER | Matching placebo administered via a pre-filled syringe |
Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. Female and male patients ≥ 18 years of age. 3. Subjects must have biopsy-confirmed forms of cutaneous lichen planus (CLP), mucosal lichen planus (MLP), or active lichen planopilaris (LPP) eligibl...
Secukinumab Q4W is being investigated for the treatment of lichen planus, specifically cutaneous lichen planus, mucosal lichen planus, and lichen planopilaris. It is a small molecule developed by Novartis AG for use in dermatology. The drug is currently in Phase 2 clinical development for these conditions.
Secukinumab Q4W is a small molecule, but its specific molecular target has not been disclosed in the available information. The drug is being studied for its efficacy and safety in patients with lichen planus, a chronic inflammatory condition affecting the skin and mucous membranes.
Secukinumab Q4W is developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. The company is conducting clinical trials to evaluate the drug's potential in treating various forms of lichen planus.
Secukinumab Q4W is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy in patients with lichen planus.
Secukinumab Q4W is being studied in a Phase 2 clinical trial with the identifier NCT04300296. This trial, titled 'PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus,' has been completed. It enrolled 111 participants across the United States, France, and Germany.
Secukinumab Q4W is a specific dosing regimen of secukinumab, administered every four weeks. The drug is being investigated for lichen planus, and the clinical trial NCT04300296 evaluated a 300 mg dose given on this schedule. The drug is developed by Novartis AG.